Hospital
MCHS Hospitals INC
MCHS Hospitals INC was paid $12.41M by Medicaid between Aug 2018 and Dec 2024, across 366 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 16% of everything it billed.
33Billing provider infoMCHS HOSPITALS INC
EAU CLAIRE, WI 54701
EAU CLAIRE, WI 54701
33aNPI1952809816assigned 01/25/2018
33bProvider typeGeneral Acute Care Hospital
28Total paid$12.41M
24GClaims557,531
24DCodes billed366
24AFirst – last monthAug 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Wisconsin
Rank by total paid#15 of 60
Median peer was paid$2.90M
This provider vs. median4.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official MUNSON, JOLYN controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 531 | $52.78 | |
| 2019 | 76,491 | $1.96M | |
| 2020 | 81,293 | $1.80M | |
| 2021 | 84,255 | $1.76M | |
| 2022 | 104,099 | $1.96M | |
| 2023 | 106,589 | $2.36M | |
| 2024incomplete | 104,273 | $2.58M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 16% | 33,423 | 28,992 | $2.01M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 12% | 24,152 | 21,360 | $1.47M |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | 3.1% | 6,021 | 5,158 | $381K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 3.1% | 6,853 | 6,079 | $380K |
| 96361 | Intravenous infusion, hydration; each additional hour | 2.9% | 4,180 | 2,773 | $360K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 2.4% | 2,471 | 2,253 | $295K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 2.3% | 6,428 | 5,586 | $283K |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 2.1% | 4,784 | 4,274 | $266K |
| 99244 | Office or other outpatient consultation, moderate to high complexity | 2.1% | 3,787 | 3,439 | $256K |
| 99243 | 1.9% | 3,367 | 3,073 | $242K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 1.8% | 3,675 | 3,295 | $219K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.7% | 36,029 | 27,110 | $208K |
354 more codes
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 1.7% | 3,267 | $205K |
| 80053 | Comprehensive metabolic panel | 1.5% | 14,217 | $188K |
| 99204 | Doctor's office visit, new patient (more involved) | 1.3% | 2,869 | $159K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.3% | 2,866 | $155K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 1.2% | 2,767 | $150K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.2% | 1,744 | $145K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 1.2% | 2,229 | $145K |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | 1.2% | 3,050 | $144K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 1.1% | 2,958 | $140K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | 1.1% | 970 | $132K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.1% | 21,980 | $131K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 1.0% | 2,359 | $128K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 2,441 | $119K |
| 92015 | Determination of refractive state | <1% | 5,285 | $111K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 692 | $110K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,788 | $108K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 7,598 | $106K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 4,539 | $103K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,398 | $96K |
| 99285 | Emergency room visit (most serious) | <1% | 2,634 | $95K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 1,324 | $93K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 3,065 | $91K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 1,474 | $89K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,840 | $82K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 5,190 | $77K |
| 20610 | <1% | 1,607 | $74K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,721 | $74K |
| 92004 | Ophthalmological services: medical examination and evaluation, comprehensive, new patient | <1% | 1,243 | $74K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,668 | $73K |
| 80061 | Lipid panel | <1% | 4,374 | $73K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 661 | $72K |
| 81025 | <1% | 4,495 | $72K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 1,237 | $65K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 5,983 | $58K |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 932 | $54K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 938 | $54K |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 106 | $53K |
| 90670 | <1% | 1,637 | $52K | |
| 87081 | <1% | 1,293 | $50K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,307 | $47K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 854 | $46K |
| 99245 | <1% | 781 | $45K | |
| 59025 | Fetal non-stress test | <1% | 716 | $45K |
| 90674 | <1% | 3,539 | $44K | |
| 81001 | <1% | 11,141 | $42K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 606 | $42K |
| 82962 | <1% | 5,180 | $42K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 4,333 | $41K |
| 83880 | <1% | 1,235 | $37K | |
| 96415 | <1% | 722 | $36K | |
| 80050 | General health panel | <1% | 2,551 | $35K |
| 99401 | <1% | 812 | $35K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 918 | $32K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 713 | $32K |
| 84484 | <1% | 3,828 | $31K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 927 | $29K |
| 87186 | <1% | 1,426 | $29K | |
| 85610 | <1% | 3,801 | $28K | |
| 82728 | <1% | 1,516 | $28K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 411 | $28K |
| 96132 | <1% | 454 | $27K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 896 | $26K |
| 90715 | <1% | 1,759 | $25K | |
| 87634 | <1% | 487 | $25K | |
| 96139 | <1% | 321 | $23K | |
| 81513 | <1% | 271 | $21K | |
| 90651 | <1% | 607 | $21K | |
| 83605 | <1% | 1,993 | $21K | |
| 94060 | <1% | 1,277 | $21K | |
| 96138 | <1% | 401 | $20K | |
| 99205 | Prolong outpt/office vis | <1% | 426 | $20K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 7,368 | $20K |
| 90680 | <1% | 1,199 | $20K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,567 | $20K |
| 91322 | <1% | 356 | $19K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 307 | $19K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 4,601 | $19K |
| 88142 | <1% | 1,065 | $18K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 517 | $18K |
| 99242 | <1% | 300 | $17K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 182 | $17K |
| 87210 | <1% | 1,648 | $16K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 3,827 | $16K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 328 | $15K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 3,032 | $15K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 898 | $15K |
| 86803 | <1% | 1,092 | $15K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 369 | $15K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 228 | $15K |
| 73630 | <1% | 2,125 | $14K | |
| 92341 | <1% | 109 | $14K | |
| 96367 | <1% | 288 | $13K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 312 | $13K |
| 84702 | <1% | 316 | $13K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 519 | $13K |
| 83735 | <1% | 3,346 | $13K | |
| 83690 | <1% | 2,996 | $13K | |
| 92340 | Fitting of spectacles, except for aphakia; monofocal | <1% | 732 | $12K |
| 86850 | <1% | 2,238 | $12K | |
| 90633 | <1% | 635 | $12K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 228 | $12K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 2,236 | $12K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 155 | $11K |
| 83615 | <1% | 4,018 | $11K | |
| 73030 | <1% | 1,444 | $11K | |
| 85018 | <1% | 1,804 | $11K | |
| 90619 | <1% | 211 | $10K | |
| 20611 | <1% | 104 | $10K | |
| 97597 | <1% | 326 | $10K | |
| 87340 | <1% | 1,248 | $10K | |
| 93976 | <1% | 424 | $10K | |
| 86140 | <1% | 2,827 | $9K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 158 | $9K |
| 85027 | <1% | 1,273 | $9K | |
| 90686 | <1% | 740 | $9K | |
| 0001A | <1% | 618 | $8K | |
| 93017 | <1% | 271 | $8K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 308 | $8K |
| 87481 | <1% | 271 | $8K | |
| 0002A | <1% | 581 | $8K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 4,669 | $8K |
| 85379 | <1% | 1,178 | $8K | |
| 82607 | <1% | 512 | $8K | |
| 86780 | <1% | 871 | $7K | |
| 83970 | <1% | 249 | $7K | |
| 87088 | <1% | 482 | $7K | |
| 82248 | <1% | 2,154 | $7K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 4,585 | $7K |
| 87070 | <1% | 696 | $7K | |
| 69210 | <1% | 177 | $7K | |
| 92083 | <1% | 529 | $6K | |
| 83550 | <1% | 1,043 | $6K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 113 | $6K |
| 86703 | <1% | 575 | $6K | |
| 90480 | <1% | 298 | $6K | |
| 84439 | <1% | 758 | $5K | |
| 73110 | <1% | 596 | $5K | |
| 86618 | <1% | 314 | $5K | |
| 90756 | <1% | 438 | $5K | |
| 94729 | <1% | 1,280 | $5K | |
| 84145 | <1% | 229 | $5K | |
| 64483 | <1% | 29 | $5K | |
| 76801 | <1% | 166 | $5K | |
| 0004A | <1% | 60 | $5K | |
| 92557 | <1% | 218 | $5K | |
| 90698 | <1% | 864 | $5K | |
| 80076 | <1% | 389 | $5K | |
| 90734 | <1% | 226 | $5K | |
| 87077 | <1% | 599 | $4K | |
| 80306 | <1% | 237 | $4K | |
| 82784 | <1% | 297 | $4K | |
| 76536 | <1% | 132 | $4K | |
| 76830 | Ultrasound, transvaginal | <1% | 194 | $4K |
| 73610 | <1% | 891 | $4K | |
| 83540 | <1% | 1,103 | $4K | |
| Q3014 | Telehealth originating site facility fee | <1% | 2,199 | $4K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 46 | $4K |
| 92012 | Ophthalmological services: medical examination and evaluation, intermediate, established patient | <1% | 104 | $4K |
| 82565 | <1% | 1,062 | $4K | |
| 88720 | <1% | 164 | $4K | |
| 93971 | <1% | 173 | $4K | |
| G0378 | Hospital observation service, per hour | <1% | 986 | $4K |
| 85730 | <1% | 1,219 | $4K | |
| 90744 | <1% | 383 | $4K | |
| 73130 | <1% | 1,217 | $3K | |
| G0008 | Administration of influenza virus vaccine | <1% | 3,007 | $3K |
| 82043 | <1% | 422 | $3K | |
| 83655 | <1% | 102 | $3K | |
| 73562 | <1% | 1,316 | $3K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 77 | $3K |
| 86900 | <1% | 1,539 | $3K | |
| 86901 | <1% | 1,529 | $3K | |
| 85652 | <1% | 1,713 | $3K | |
| 82977 | <1% | 923 | $3K | |
| 72100 | <1% | 426 | $3K | |
| 87653 | <1% | 85 | $3K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 146 | $3K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 505 | $3K |
| 96136 | <1% | 62 | $3K | |
| 82803 | <1% | 158 | $3K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 95 | $2K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 82 | $2K |
| 11102 | <1% | 26 | $2K | |
| 73502 | <1% | 572 | $2K | |
| 82570 | <1% | 617 | $2K | |
| 86038 | <1% | 321 | $2K | |
| 31575 | <1% | 73 | $2K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 28,775 | $2K |
| 0012A | <1% | 116 | $2K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 24 | $2K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 28 | $2K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 15 | $2K |
| 87040 | <1% | 244 | $2K | |
| 73560 | <1% | 191 | $2K | |
| 73221 | <1% | 30 | $2K | |
| G0330 | Facility services for dental rehabilitation procedure(s) performed on a patient who requires monitored anesthesia (e.g., general, intravenous sedation (monitored anesthesia care) and use of an operating room | <1% | 17 | $2K |
| 99001 | <1% | 108 | $2K | |
| 82950 | <1% | 308 | $2K | |
| 71045 | Radiologic examination, chest; single view | <1% | 1,740 | $2K |
| 82077 | <1% | 173 | $2K | |
| 93325 | <1% | 55 | $1K | |
| 84460 | <1% | 471 | $1K | |
| 81003 | <1% | 89 | $1K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 4,509 | $1K |
| 72141 | <1% | 43 | $1K | |
| 87205 | <1% | 589 | $1K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 335 | $1K |
| 36591 | <1% | 1,037 | $1K | |
| 90661 | <1% | 193 | $1K | |
| 76770 | <1% | 29 | $1K | |
| 74018 | <1% | 204 | $1K | |
| 92567 | <1% | 202 | $1K | |
| 92133 | <1% | 521 | $1K | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 47 | $1K |
| 0011A | <1% | 96 | $1K | |
| 90656 | <1% | 221 | $1K | |
| 20553 | <1% | 46 | $1K | |
| 94726 | <1% | 256 | $1K | |
| G0127 | Trimming of dystrophic nails, any number | <1% | 54 | $1K |
| 71250 | <1% | 66 | $1K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 13 | $940.10 |
| 84703 | <1% | 68 | $918.46 | |
| 84450 | <1% | 200 | $907.97 | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 64 | $872.52 |
| 90677 | <1% | 304 | $825.69 | |
| 17000 | <1% | 27 | $765.80 | |
| 90688 | <1% | 13 | $759.64 | |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | <1% | 126 | $728.49 |
| 86706 | <1% | 114 | $727.91 | |
| 0031A | <1% | 37 | $688.68 | |
| 96116 | <1% | 15 | $686.24 | |
| 90697 | <1% | 518 | $672.41 | |
| 87469 | <1% | 28 | $669.51 | |
| 87484 | <1% | 28 | $669.51 | |
| 87468 | <1% | 28 | $669.51 | |
| 86480 | <1% | 17 | $652.56 | |
| 99385 | <1% | 15 | $632.12 | |
| 86364 | <1% | 74 | $571.99 | |
| 95886 | <1% | 15 | $526.32 | |
| 72110 | <1% | 167 | $519.82 | |
| 96376 | <1% | 921 | $483.68 | |
| 90716 | <1% | 16 | $483.01 | |
| 82550 | <1% | 137 | $479.34 | |
| 86762 | <1% | 41 | $463.07 | |
| 90662 | <1% | 303 | $423.22 | |
| 90381 | <1% | 16 | $422.73 | |
| 82785 | <1% | 19 | $413.77 | |
| 90687 | <1% | 13 | $398.44 | |
| 84100 | <1% | 181 | $390.48 | |
| 84156 | <1% | 148 | $377.45 | |
| 86704 | <1% | 53 | $370.73 | |
| 86708 | <1% | 51 | $368.38 | |
| 90710 | <1% | 16 | $326.76 | |
| 82746 | <1% | 46 | $316.04 | |
| J2704 | Injection, propofol, 10 mg | <1% | 6,241 | $308.50 |
| 76942 | <1% | 27 | $277.85 | |
| 80143 | <1% | 19 | $224.55 | |
| 90750 | <1% | 54 | $223.28 | |
| 36592 | <1% | 2,809 | $222.40 | |
| 82330 | <1% | 35 | $198.52 | |
| 86036 | <1% | 30 | $194.36 | |
| 80179 | <1% | 17 | $179.82 | |
| 92579 | <1% | 12 | $168.59 | |
| 90707 | <1% | 41 | $164.95 | |
| 85007 | <1% | 69 | $154.26 | |
| 97161 | <1% | 50 | $149.01 | |
| 86200 | <1% | 19 | $148.26 | |
| 82105 | <1% | 12 | $147.66 | |
| 72040 | <1% | 64 | $134.27 | |
| 0124A | <1% | 84 | $118.68 | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 19 | $109.55 |
| 90696 | <1% | 16 | $108.78 | |
| 74019 | <1% | 65 | $94.72 | |
| 99383 | <1% | 16 | $88.32 | |
| 97162 | <1% | 46 | $87.90 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 461 | $76.59 |
| 87185 | <1% | 20 | $74.15 | |
| 91321 | <1% | 22 | $68.18 | |
| 0094A | <1% | 25 | $64.20 | |
| 82150 | <1% | 22 | $60.43 | |
| G0476 | Infectious agent detection by nucleic acid (dna or rna); human papillomavirus (hpv), high-risk types (e.g., 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) for cervical cancer screening, must be performed in addition to pap test | <1% | 62 | $51.55 |
| 73080 | <1% | 19 | $47.13 | |
| 86431 | <1% | 14 | $41.14 | |
| 88342 | <1% | 32 | $33.72 | |
| 82947 | <1% | 13 | $28.50 | |
| 82040 | <1% | 12 | $27.89 | |
| 88304 | <1% | 182 | $25.98 | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 214 | $24.13 |
| C1769 | Guide wire | <1% | 130 | $15.37 |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 29 | $12.39 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,472 | $7.33 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 5,692 | $2.67 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 5,579 | $1.64 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 136 | $1.13 |
| J3490 | Unclassified drugs | <1% | 2,537 | $1.03 |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 52 | $0.91 |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 2,273 | $0.41 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 679 | $0.27 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 7,766 | $0.07 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 5,620 | $0.02 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 5,740 | $0.02 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 6,461 | $0.01 |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | 0% | 561 | $0.00 |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | 0% | 2,203 | $0.00 |
| J7030 | Infusion, normal saline solution , 1000 cc | 0% | 1,702 | $0.00 |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 3,641 | $0.00 |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 343 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 890 | $0.00 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 459 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 43 | $0.00 |
| V5266 | Battery for use in hearing device | 0% | 40 | $0.00 |
| 92020 | 0% | 39 | $0.00 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 258 | $0.00 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 72 | $0.00 |
| J0136 | Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg | 0% | 31 | $0.00 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 236 | $0.00 |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | 0% | 54 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 35 | $0.00 |
| 73140 | 0% | 32 | $0.00 | |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 26 | $0.00 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 47 | $0.00 |
| 72050 | 0% | 12 | $0.00 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 15 | $0.00 |
| C1760 | Closure device, vascular (implantable/insertable) | 0% | 12 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 15 | $0.00 |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 13 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 28 | $0.00 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | 0% | 600 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 1,625 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 241 | $0.00 |
| A9270 | Non-covered item or service | 0% | 3,592 | $0.00 |
| J1040 | Injection, methylprednisolone acetate, 80 mg | 0% | 1,263 | $0.00 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | 0% | 345 | $0.00 |
| J1815 | Injection, insulin, per 5 units | 0% | 30 | $0.00 |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | 0% | 476 | $0.00 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 555 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 2,785 | $0.00 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 265 | $0.00 |
| G0009 | Administration of pneumococcal vaccine | 0% | 92 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 15 | $0.00 |
| C1889 | Implantable/insertable device, not otherwise classified | 0% | 75 | $0.00 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 0% | 157 | $0.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 301 | $0.00 |
| J8501 | Aprepitant, oral, 5 mg | 0% | 17 | $0.00 |
| J2469 | Injection, palonosetron hcl, 25 mcg | 0% | 35 | $0.00 |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 69 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 154 | $0.00 |
| J3535 | Drug administered through a metered dose inhaler | 0% | 79 | $0.00 |
| 94760 | 0% | 69 | $0.00 | |
| 51798 | 0% | 47 | $0.00 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 0% | 60 | $0.00 |
| C9290 | Injection, bupivacaine liposome, 1 mg | 0% | 14 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 15 | $0.00 |
| 90474 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMUNSON, JOLYN (VP REVENUE CYCLE OPERATIONS)
Parent organizationMARSHFIELD CLINIC HEALTH SYSTEM INC
| Provider | Location | Paid |
|---|---|---|
| MCHS Hospitals INC | Marshfield, WI | $45.31M |
| Marshfield Clinic INC | Marshfield, WI | $19.61M |
| MCHS Hospitals INC | Marshfield, WI | $11.82M |
| Beaver Dam Community Hospitals INC | Beaver Dam, WI | $10.58M |
| Dickinson County Healthcare System | Iron Mountain, MI | $10.23M |
| MCHS Hospitals INC | Ladysmith, WI | $7.36M |
| MCHS Hospitals INC | Weston, WI | $6.40M |
| MCHS Hospitals INC | Eau Claire, WI | $4.14M |
| MCHS Hospitals INC | Minocqua, WI | $2.90M |
| Dickinson County Healthcare System | Iron Mountain, MI | $2.44M |
| Dickinson County Healthcare System | Iron Mountain, MI | $2.29M |
| MCHS Hospitals INC | Wausau, WI | $1.84M |
| MCHS Hospitals INC | Weston, WI | $1.22M |
| MCHS Hospitals INC | Minocqua, WI | $1.16M |
| MCHS Hospitals INC | Marshfield, WI | $988K |
| MCHS Hospitals INC | Ladysmith, WI | $867K |
| Beaver Dam Community Hospitals INC | Beaver Dam, WI | $847K |
| Dickinson County Healthcare System | Iron Mountain, MI | $648K |
| MCHS Hospitals INC | Marshfield, WI | $563K |
| MCHS Hospitals INC | Minocqua, WI | $338K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.